Down-regulation of RBM3 significantly reduces cisplatin sensitivity in ovarian cancer cells. siRBM3 transfected A2780 cells were, 24 hrs post-transfection, treated with various concentrations of cisplatin for 1 h followed by 48 hrs culture in fresh drug-free media. (A) Cell viability was evaluated by WST-1 assay in siRBM3 transfected A2780 cells treated with cisplatin (1, 5, 10, 25, 50 and 100 μM). Data are presented as mean values from six independent experiments performed in triplicates presented as percentage of viable cells as compared with untreated cells. Error bars represent SEM. (B) Cell cycle phase distribution and (C) fraction of apoptotic cells were analysed by flow cytometry in siRBM3 transfected A2780 cells treated with 50 μM cisplatin. Data are presented as mean value from four independent experiments presented as fold change of cisplatin treatment. Error bars represent SEM.